How China Is Reshaping Big Pharma

BEIJING – Roughly half of the new medicines entering human trials may now begin in Chinese laboratories, according to the figures discussed in the video. Western drugmakers aren’t waiting years to develop every replacement themselves. They are paying Chinese biotech companies for promising compounds, early trial data, and a head start.

That shift matters because several blockbuster drugs face patent expirations before 2030. The companies with the biggest research budgets are buying time, while China is building the laboratories, factories, and insurance systems that could give it more control over the entire medicine supply chain.

The Patent Cliff Is Forcing Big Pharma to Shop for New Drugs

Merck’s cancer treatment Keytruda shows why pharmaceutical companies are looking overseas for new products. The drug generated $31.7 billion in sales in one year, according to Merck’s own report on Keytruda revenue. That is close to half of the company’s total sales.

The problem is the patent calendar. The video identifies December 2028 as a major expiration date for Keytruda protection. Once the relevant patents expire, rival manufacturers can begin selling competing versions, which puts a large part of Merck’s revenue at risk.

A blockbuster drug creates an unusual problem for its owner. Success makes the eventual loss more painful because the company has to replace an enormous stream of revenue, not merely launch another product.

Merck isn’t the only company facing this pressure. The video says more than $300 billion in prescription drug sales could lose patent protection before 2030, equal to roughly one-fifth of the industry’s sales.

Why Big Pharma can’t simply invent a replacement

The traditional drug-development process starts with a molecule in a laboratory. Researchers then test it in humans, run larger clinical trials, submit the results to regulators, and build the manufacturing and sales operation needed to supply patients.

That process is expensive and slow. The video estimates that bringing one new drug to market costs a major pharmaceutical company around $2.2 billion. The period from the first human trial to approval can approach eight years.

A company that starts testing a molecule today may not have a product in pharmacies until the mid-2030s. That timeline is too long to solve a patent problem arriving in 2028.

So the business model has changed. Rather than begin with an untested idea, a Western drugmaker can license a compound that has already gone through early testing in China. The buyer receives the molecule and some clinical data, then takes over later development.

Big Pharma is buying time before its biggest patents expire.

The New Business Model: Buy the Molecule, Save the Time

A Chinese biotech company may offer a Western partner a drug candidate that already has laboratory work, manufacturing plans, and early human trial data behind it. The asset still carries risks, but the buyer doesn’t have to spend years proving that the molecule can reach human testing.

After a licensing agreement, the Western company may fund global trials, handle regulatory submissions, arrange production, and sell the treatment outside China under its own brand. The Chinese company receives an upfront payment and additional money if the drug reaches later milestones.

This arrangement explains why Pfizer, AstraZeneca, Merck, and GSK are looking at Chinese biotech assets. Their goal isn’t necessarily to buy an entire Chinese company. Often, they want rights to one molecule or a group of drug programs.

The GSK and HutchMed deal

The video highlights a 2025 agreement between GSK and HutchMed. The deal included $500 million in upfront cash, rights to as many as 12 drug programs, and up to $12.5 billion in possible future payments.

Those numbers sound enormous, but they describe two very different things. The $500 million changes hands when the agreement is signed. The $12.5 billion depends on future clinical, regulatory, and commercial milestones.

That structure lets a Western company access a promising pipeline without paying the full headline value on day one. It also gives the Chinese company immediate cash at a time when domestic investment has become harder to find.

The Chinese Scientists Behind the Deals

Michelle Xia’s Western training

The rise of Chinese biotech didn’t happen in isolation. Many of the scientists leading Chinese companies trained inside Western universities and pharmaceutical firms.

Michelle Xia is one example. Her background, as described in the video, includes a biochemistry degree in Guangzhou, a doctorate in England, cancer research in Kentucky, work at Bayer in California, and a position at an antibody company in the San Francisco Bay Area.

She later ran a joint venture created by Pfizer and her former employer. In other words, Western pharmaceutical companies helped develop the skills and experience that Chinese biotech founders later used to build competing drug-discovery businesses.

That movement of talent matters because drug development depends on more than laboratory knowledge. Scientists also need experience with clinical trials, regulatory standards, manufacturing, and licensing negotiations.

The creation of Akeso

In 2012, Xia and three other scientists started Akeso in Zhongshan, Guangdong. The founding team had less than $3 million, took no salaries, and hired recent university graduates because the company couldn’t afford established researchers.

The strategy was practical rather than glamorous. A small team focused on developing antibody treatments with limited capital, then searched for partners willing to pay for promising candidates.

Three years later, Merck bought Akeso’s first molecule, according to the account in the video. That early transaction showed that a Chinese laboratory could produce research valuable to one of the largest pharmaceutical companies in the United States.

Ivonescimab Shows Why Western Companies Accept the Risk

The molecule at the center of the video is Akeso’s ivonescimab, also known as AK112. Akeso describes it as a bispecific antibody that combines PD-1 immunotherapy with VEGF targeting, a design intended to help the immune system attack cancer while also interfering with the blood-vessel growth that tumors need. The company’s announcement of the Summit licensing agreement identifies the deal and its $500 million upfront payment.

The video describes two important comparisons involving the drug. In one lung cancer trial, ivonescimab performed better than Keytruda on the time patients went before their cancer returned. At a later cancer conference, the treatment reportedly showed 34% fewer deaths than a competing immunotherapy.

Those results, if confirmed through the full regulatory process, would make the drug commercially important. Yet strong early results don’t automatically produce approval in every country.

A promising drug can remain unavailable.

Summit Therapeutics agreed to pay $500 million upfront in 2022 for rights to develop and commercialize the drug outside China. The deal’s total potential value was reported as up to $5 billion in Akeso’s original announcement.

At the time described in the video, ivonescimab still wasn’t approved in the United States. The global trial data hadn’t produced survival results that American regulators considered sufficient for approval.

That leaves Summit in a difficult position. The company paid a large upfront amount for a promising drug, but it still couldn’t sell the treatment to an American patient. The investment may pay off later, but the buyer accepted years of uncertainty in exchange for access to a potentially valuable asset.

The deal also illustrates the balance of power in modern drug development. Chinese researchers can produce a candidate with enough evidence to attract major Western financing. Western companies then assume the cost and risk of proving that the drug works across a broader patient population.

The Headline Numbers Hide the Real Cash Flow

The video cites 157 licensing deals signed by Chinese laboratories in one year, with press releases adding up to $135.7 billion in possible value. However, roughly $7 billion had actually been paid.

That gap isn’t unusual in biotechnology. A licensing contract can include several layers of conditional payments:

• The buyer pays an upfront amount when the agreement is signed.
• Additional payments arrive if the drug passes clinical trials.
• Regulatory milestones trigger more money after approval.
• Sales milestones produce further payments if doctors and patients adopt the treatment.

Most experimental drugs don’t survive every stage. When a trial fails,s or a regulator rejects an application, the milestone payment disappears.

The GSK and HutchMed agreement makes the distinction clear. The headline figure reached $12.5 billion, but the cash exchanged immediately was $500 million. For biotech founders, that first payment can matter more than a much larger figure that may never arrive.

Why Chinese biotech companies accept these deals

Chinese drugmakers face a difficult domestic pricing system. When a company wants a medicine covered by China’s national insurance system, it negotiates with the government, which pushes the price down.

The video says companies included in the latest insurance list gave up 63% of the price they initially requested. A laboratory can create an excellent cancer drug and still struggle to earn enough from sales at home.

At the same time, Chinese venture capital has weakened. That leaves some companies with valuable research but not enough money to keep paying scientists, running trials, or maintaining facilities.

Licensing offers an immediate source of funding. The Chinese company gives up some future control or revenue, but it receives cash now. The Western buyer gets a drug program that has already crossed some of the most expensive early steps.

Upfront payments are rising.

The average upfront payment for these licenses rose from $52 million three years ago to $172 million in 2026, according to the figures presented in the video.

Chinese laboratories are asking for more because their compounds have become more attractive and Western patent deadlines are drawing closer. Meanwhile, pharmaceutical executives have fewer years available to develop replacement products internally.

Neither side has complete control. The Chinese company needs cash, while the Western company needs a faster route to a new medicine. That shared pressure explains why deals can move quickly and why upfront prices keep rising.

Europe Already Lost Control of a Basic Medicine Supply Chain

Paracetamol shows how dependency develops.

Paracetamol, known as acetaminophen in the United States, is one of Europe’s most common medicines. The active pharmaceutical ingredient, or API, is the chemical inside the tablet that produces the medical effect.

European production of paracetamol’s API ended in 2008 after the last French plant closed. Asian manufacturers could supply the ingredient at a lower price, so European buyers turned elsewhere.

No single government had to announce a decision to abandon the supply chain. Purchasing managers made smaller cost-based choices over many years. Each decision appeared sensible at the time, but the combined result was a serious dependence on overseas suppliers.

Supply chains can become dependent without one clear moment when anyone decides to create that dependence.

Europe’s falling share of API production

The video says Europe once produced more than 80% of the world’s active pharmaceutical ingredients by value. Today, its share is around 30%, while China’s is approximately 35%.

The exact percentages vary by medicine and by how researchers measure production. Still, the direction is clear. Europe has lost manufacturing capacity, particularly for low-margin ingredients where Asian producers can operate at lower cost.

France has tried to bring paracetamol production back. The obstacle is the price gap. Manufacturing the ingredient in France costs about 60% more than buying it from Asia.

Research from the Mercator Institute for China Studies on Europe’s drug dependence also describes Europe’s reliance on Chinese production for important medical ingredients.

The lesson is uncomfortable for drug companies and governments alike. A supply chain optimized for the lowest price can become expensive to rebuild once factories, workers, and technical knowledge have moved elsewhere.

American Biotech Is Becoming a Wrapper for Chinese Science

A similar pattern is appearing in the United States, but this time the product being imported is a drug candidate rather than a basic chemical ingredient.

The model described in the video is straightforward:

1. Investors raise money in the United States.
2. The company licenses a molecule from a Chinese laboratory.
3. It registers an American corporation, often in Delaware.
4. A small team handles development, fundraising, and commercialization.
5. Investors value the company as a US biotech business even though the original discovery happened in China.

This doesn’t mean the American company contributes nothing. It may run global trials, manage regulatory work, arrange manufacturing, and build a sales organization. However, it may not have discovered the underlying molecule.

Why investors prefer drugs already in human trials

Investors prefer evidence over promises. A company with a drug already tested in humans has cleared a major hurdle, while a laboratory project may still be years away from showing whether it works in patients.

The video says two-thirds of American biotech funding rounds in the first half of the year went to companies that already had a drug in human testing. That preference pushes money toward later-stage programs.

An American scientist with a new idea may need eight years and billions of dollars to reach the same stage that a Chinese laboratory has already reached. A company that licenses the Chinese asset can move faster, at least on paper.

The result is a tougher funding environment for early-stage American research. The video also cites 219 US biotech companies shutting down over four years, while cautioning that those closures don’t all have one cause.

The Biosecure Act Leaves Licensing Open

Congress passed the Biosecure Act in December 2025, according to the timeline discussed in the video. The law restricts certain federal contracts and grants involving designated Chinese biotechnology service providers. A legal analysis of the BIOSECURE Act describes its limits on US government contracting with biotechnology companies of concern.

The law addresses public money and specific service relationships. It doesn’t stop an American company from licensing a drug molecule that a Chinese laboratory discovered.

That creates a gap between political scrutiny and commercial behavior. Washington can restrict federal agencies from working with certain Chinese biotech firms while private pharmaceutical companies continue buying access to Chinese drug candidates.

A separate analysis of the act’s federal procurement and grant restrictions explains why the law doesn’t amount to a full ban on China-US biotech transactions.

The law targets some Chinese biotech services, but it doesn’t end the flow of Chinese drug candidates into American companies.

Patients Face Different Prices and Waiting Times

The video says more than 40,000 patients in China had already received the drug discussed in the story while American approval remained pending.

That difference can occur because a medicine discovered in China enters Chinese trials first. Chinese patients may gain earlier access, while US regulators wait for more data from trials involving patients in other regions and populations.

Regulatory caution can protect patients, but it also creates an uneven schedule. A treatment may be available in one country while patients elsewhere wait several more years for approval.

The same science can carry different prices.

The video gives a striking comparison: a treatment costing up to $475,000 in the United States may cost as little as $140,000 in China.

The difference comes from how each market handles price. Chinese government negotiations can reduce domestic prices, while an American license holder may set a much higher commercial price to recover research, trial, regulatory, manufacturing, and sales costs.

The comparison isn’t a claim that every drug costs exactly these amounts. It shows how the same underlying science can produce different prices and different access dates depending on the country.

Beijing Is Building More Than a Drug Pipeline

China’s five-year plan through 2030 places biology near the top of its technology priorities. The video compares this focus with earlier state-backed efforts in electric vehicles and solar panels.

Biology appears twice in the plan, as a core technology and as a future industry. That distinction matters because China isn’t focusing only on laboratory discoveries. It’s also investing in the equipment and facilities needed to manufacture biological medicines at scale.

State funding is moving into bioreactors, pilot plants, and factories connected to research laboratories. More than 20 provinces have added their own budgets and programs.

A country can license a molecule, but manufacturing capacity is harder to transfer. Once production facilities, specialized workers, supply contracts, and technical knowledge gather in one place, that network becomes a source of bargaining power.

The same issue already affects basic pharmaceutical ingredients. The Council on Foreign Relations report on pharmaceutical supply chains examines China’s role in supplying key starting materials and active pharmaceutical ingredients used for critical medicines.

China wants less dependence on Western buyers.

The video also describes a second insurance system opened in China to give domestic biotech companies a better way to charge patients. Its purpose is to reduce the pressure that pushes Chinese laboratories to license promising drugs cheaply to Western companies.

If Chinese companies can earn more at home, they won’t need Western upfront payments as urgently. That could change the negotiating balance.

Today, a Chinese laboratory may need an American or European partner to fund late-stage trials and keep the business operating. In the future, China could provide more of its own research money, manufacturing capacity, and domestic revenue.

Western companies would then be buying access to Chinese-developed treatments because China had a stronger alternative market, not because Chinese companies had no other way to survive.

The Power Shift Is Happening Inside the Contract

The current arrangement brings together two companies with different problems. A Chinese scientist may have a promising drug that earns too little under domestic price controls. An American executive may face a patent expiration that shareholders have known about for years.

Licensing solves both problems for a while. The Chinese company receives cash and a path to international development. The Western company skips part of the early research process and gains a chance to replace lost revenue.

That doesn’t mean China owns Pfizer, Merck, or GSK. The stronger claim is more precise: Chinese laboratories are gaining influence over the drug candidates that Western pharmaceutical companies need.

The advantage could increase if China continues strengthening research, manufacturing, and domestic insurance coverage at the same time. Western companies may remain important partners, but their role could shift from discovering medicines to buying, developing, branding, and selling medicines discovered elsewhere.

Trending China News:

Japan and India Build a Defense Network Around China

China’s Economic Slowdown Could Hit Global Trade

China Land Lease Renewal: Why Homeowners Are Worried